Fifty patients received 8 intradermal IC41 vaccinations biweekly with topical application of the TLR7 agonist imiquimod (Group A). In Group B, 21 patients received a condensed schedule of 16 subcutaneous vaccinations weekly without imiquimod.
At Week 16 Group A (n = 44) showed a statistically significant (p = 0.0013) HCV viral load decline of 0.21 log. 24 weeks after the last vaccination the viral load decreased by 0.47 log (p < 0.0001) in 34 subjects. This effect was more pronounced in 17 patients with high baseline HCV (>2 脳 106 IU/ml) with a 0.61 log decline, which was statistically significant (p < 0.02) starting two weeks after the third vaccination. No apparent effect on HCV viral load was observed in Group B (n = 21). In Group A eight patients (24%) showed a viral load response defined as a decline of >0.8 log. Overall, about 30-55%of patients showed T cell responses during the vaccination series and up to six months in both groups. No significant correlations between the HCV viral load decrease and T cell immune response were detected.
This is the first report on a significant antiviral effect of a peptide vaccine in HCV infected patients. Response kinetics with increased HCV RNA decline 24 weeks after the last IC41 vaccination is encouraging.